#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Mark Leuchtenberger Email
CEO . SpyBiotech
Oxford,
Locationm******************@spybiotech.com
Primary EmailHow to contact Mark Leuchtenberger
Join and see Mark's contact info for free!Current Roles
Employees:
26Revenue:
$4MAbout
SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimises delivery risk and enhances immunogenicity and efficacy. SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialise and sub-license the SpyTag/SpyCatcher technology in vaccine development. The company's current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for 2021. SpyBiotech is supported by high quality investors including Oxford Sciences Innovation (OSI), the capital investor for the University of Oxford, and GV (formally Google Ventures). The company has raised £15 million of funding to date.SpyBiotech Address
7600 Quorum Oxford Business Park NorthOxford, null